Shinobi Therapeutics

0 followers


Shinobi Therapeutics is developing a new class of hypoimmune CD8ab iPS-T cells for cancer and beyond by using immune evasion to unlock the full potential of iPSCs.

Employees

11-50

Links

Org chart

Dan Kemp
Chief Executive Officer

Dan Kemp

Collapse
Bhanu Iyer
VP US Operations & HR
Ryosuke Gonotsubo
Chief Of Staff

Teams

This company has no teams yet